Pixatimod - Zucero Therapeutics

Drug Profile

Pixatimod - Zucero Therapeutics

Alternative Names: PG-545

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Progen Pharmaceuticals
  • Developer Bristol-Myers Squibb; Medigen Biotechnology Corporation; Progen Pharmaceuticals Limited; TBG Diagnostics Limited; Zucero Therapeutics
  • Class Antineoplastics; Glycosaminoglycans; Oligosaccharides; Small molecules
  • Mechanism of Action Dendritic cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer; Solid tumours
  • Preclinical Hepatocellular carcinoma
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Australia (IV, Infusion)
  • 24 Oct 2017 Phase-I clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (ACTRN12617001573347)
  • 24 Oct 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Australia (IV) (ACTRN12617001573347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top